Ladenburg Thalmann Upgrades Compass Therapeutics to Buy, Announces $5 Price Target
Portfolio Pulse from Benzinga Newsdesk
Ladenburg Thalmann has upgraded Compass Therapeutics (NASDAQ:CMPX) from Neutral to Buy, setting a price target of $5.
September 16, 2024 | 1:27 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Compass Therapeutics has been upgraded by Ladenburg Thalmann from Neutral to Buy, with a new price target of $5.
The upgrade from Neutral to Buy by a reputable analyst firm like Ladenburg Thalmann is likely to positively influence investor sentiment and could lead to an increase in CMPX's stock price in the short term. The announcement of a specific price target of $5 provides a clear valuation benchmark for investors.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100